INMB Inmune Bio, Inc.

8-K Current Report

Filed: February 23, 2026

Health Care

Biological Products, (No Diagnostic Substances)

Inmune Bio, Inc. (INMB) 8-K current report filed with SEC EDGAR on February 23, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.

Reported 8-K Items
1 item

Item 8.01: Other Events

AI Filing Analysis
8-K

Item 8.01 · Other Events

• Webinar Feb 27, 2026 at 9:30 a.m. ET covering XPro1595 registrational pathway for early Alzheimer's disease
• Registrational pathway detail signals INMB advancing toward pivotal trial or FDA approval strategy for XPro™

+1 more insights

Other Inmune Bio, Inc. 8-K Filings

8-K Feb 27, 2026

Get deeper insights on Inmune Bio, Inc.

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.